Strong complement activation after acute ischemic stroke is associated with unfavorable outcomes

Atherosclerosis

Volumn 204, Issue 1, 2009, Pages 315-320

  Széplaki, Gábor ^a   Szegedi, Róbert ^a   Hirschberg, Kristóf ^b   Gombos, Tímea ^a   Varga, Lilian ^a   Karádi, István ^a,b   Entz, László ^a   Széplaki, Zoltán ^a   Garred, Peter ^c   Prohászka, Zoltán ^a,d   Füst, George ^a,c  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c University of Copenhagen   (Denmark)

^d INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

C3a; C4d; C5b 5; Complement; Complement activation; Ischemic stroke; MBL; Stroke

Indexed keywords

C REACTIVE PROTEIN; COMPLEMENT; COMPLEMENT COMPONENT C1R; COMPLEMENT COMPONENT C1S; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4D; COMPLEMENT COMPONENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DISABILITY; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HUMAN; MALE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CEREBRAL INFARCTION; COMPLEMENT ACTIVATION; COMPLEMENT C1 INACTIVATOR PROTEINS; COMPLEMENT C1R; COMPLEMENT C3A; COMPLEMENT C4B; COMPLEMENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; DISABILITY EVALUATION; FEMALE; HUMANS; MALE; MANNOSE-BINDING LECTIN; MIDDLE AGED; PEPTIDE FRAGMENTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; STROKE; TIME FACTORS;

EID: 67349147890     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.07.044     Document Type: Article

References (32)

1. Danton G.H., and Dietrich W.D. Inflammatory mechanisms after ischemia and stroke. J Neuropathol Exp Neurol 62 (2003) 127-136
2. Smith C.J., Emsley H.C., Gavin C.M., et al. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol 4 (2004) 2
3. Christensen H., and Boysen G. C-reactive protein and white blood cell count increases in the first 24 h after acute stroke. Cerebrovasc Dis 18 (2004) 214-219
4. D'Ambrosio A.L., Pinsky D.J., and Connolly E.S. The role of the complement cascade in ischemia/reperfusion injury: implications for neuroprotection. Mol Med 7 (2001) 367-382
5. Van Beek J., Bernaudin M., Petit E., et al. Expression of receptors for complement anaphylatoxins C3a and C5a following permanent focal cerebral ischemia in the mouse. Exp Neurol 161 (2000) 373-382
6. Pedersen E.D., Aass H.C., Rootwelt T., et al. CD59 efficiently protects human NT2-N neurons against complement-mediated damage. Scand J Immunol 66 (2007) 345-351
7. Mocco J., Mack W.J., Ducruet A.F., et al. Complement component C3 mediates inflammatory injury following focal cerebral ischemia. Circ Res 99 (2006) 209-217
8. Atkinson C., Zhu H., Qiao F., et al. Complement-dependent P-selectin expression and injury following ischemic stroke. J Immunol 177 (2006) 7266-7274
9. Arumugam T.V., Tang S.C., Lathia J.D., et al. Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc Natl Acad Sci USA 104 (2007) 14104-14109
10. Vasthare U.S., Barone F.C., Sarau H.M., et al. Complement depletion improves neurological function in cerebral ischemia. Brain Res Bull 45 (1998) 413-419
11. Figueroa E., Gordon L.E., Feldhoff P.W., and Lassiter H.A. The administration of cobra venom factor reduces post-ischemic cerebral injury in adult and neonatal rats. Neurosci Lett 380 (2005) 48-53
12. Akita N., Nakase H., Kaido T., Kanemoto Y., and Sakaki T. Protective effect of C1 esterase inhibitor on reperfusion injury in the rat middle cerebral artery occlusion model. Neurosurgery 52 (2003) 395-400
13. De Simoni M.G., Storini C., Barba M., et al. Neuroprotection by complement (C1) inhibitor in mouse transient brain ischemia. J Cereb Blood Flow Metab 23 (2003) 232-239
14. Mocco J., Mack W.J., Ducruet A.F., et al. Preclinical evaluation of the neuroprotective effect of soluble complement receptor type 1 in a nonhuman primate model of reperfused stroke. J Neurosurg 105 (2006) 595-601
15. Pedersen E.D., Waje-Andreassen U., Vedeler C.A., Aamodt G., and Mollnes T.E. Systemic complement activation following human acute ischaemic stroke. Clin Exp Immunol 137 (2004) 117-122
16. Mocco J., Wilson D.A., Komotar R.J., et al. Alterations in plasma complement levels after human ischemic stroke. Neurosurgery 59 (2006) 28-33
17. Di Napoli M., Schwaninger M., Cappelli R., et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke 36 (2005) 1316-1329
18. Elkind M.S., Tai W., Coates K., Paik M.C., and Sacco R.L. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med 166 (2006) 2073-2080
19. Youssef M.Y., Mojiminiyi O.A., and Abdella N.A. Plasma concentrations of C-reactive protein and total homocysteine in relation to the severity and risk factors for cerebrovascular disease. Transl Res 150 (2007) 158-163
20. Adams H., Adams R., Del Zoppo G., and Goldstein L.B. Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke 36 (2005) 916-923
21. Brott T., Adams Jr. H.P., Olinger C.P., et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 20 (1989) 864-870
22. Mahoney F.I., and Barthel D.W. Functional evaluation: the Barthel index. Md State Med J 14 (1965) 61-65
23. Bonita R., and Beaglehole R. Recovery of motor function after stroke. Stroke 19 (1988) 1497-1500
24. Miller S.A., Dykes D.D., and Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16 (1988) 1215
25. Garred P.J.J.S., Quist L., Taaning E., and Madsen H.O. Association of mannose-binding lectin polymorphisms with sepsis and fatal outcome, in patients with systemic inflammatory response syndrome. J Infect Dis 188 (2003) 1394-1403
26. Nagy G., Brozik M., Varga L., et al. Usefulness of detection of complement activation products in evaluating SLE activity. Lupus 9 (2000) 19-25
27. Foerch C., Singer O.C., Neumann-Haefelin T., et al. Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction. Arch Neurol 62 (2005) 1130-1134
28. Bossi F., Fischetti F., Pellis V., et al. Platelet-activating factor and kinin-dependent vascular leakage as a novel functional activity of the soluble terminal complement complex. J Immunol 173 (2004) 6921-6927
29. Di Napoli M. Systemic complement activation in ischemic stroke. Stroke 32 (2001) 1443-1448
30. Korfias S., Stranjalis G., Papadimitriou A., et al. Serum S-100B protein as a biochemical marker of brain injury: a review of current concepts. Curr Med Chem 13 (2006) 3719-3731
31. Pepys M.B., Hirschfield G.M., Tennent G.A., et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 440 (2006) 1217-1221
32. Mahaffey K.W., Van de Werf F., Shernan S.K., et al. Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview. Am Heart J 152 (2006) 291-296